Prevalence of Gastrointestinal Symptoms in Severe Acute Respiratory Syndrome Coronavirus 2 Infection: Results of the Prospective Controlled Multinational GI-COVID-19 Study

Giovanni Marasco; Cesare Cremon; Maria Raffaella Barbaro; Daniele Salvi; Giulia Cacciari; Anna Kagramanova; Dmitry Bordin; Vasile Drug; Edgidia Miftode; Pietro Fusaroli; Salem Youssef Mohamed; Chiara Ricci; Massimo Bellini; M. Masudur Rahman; Luigi Melcarne; Javier Santos; Beatriz Lobo; Serhat Bor; Suna Yapali; Deniz Akyol; Ferdane Pirincci Sapmaz; Yonca Yilmaz Urun; Tugce Eskazan; Altay Celebi; Huseyin Kacmaz; Berat Ebik; Hatice Cilem Binicier; Mehmet Sait Bugdayci; Munkhtsetseg Banzragch Yaǧci; Husnu Pullukcu; Berrin Yalinbas Kaya; Ali Tureyen; Ibrahim Hatemi; Elif Sitre Koc; Goktug Sirin; Ali Riza Caliskan; Goksel Bengi; Esra Ergun Alis; Snezana Lukic; Meri Trajkovska; Keren Hod; Dan Dumitrascu; Antonello Pietrangelo; Elena Corradini; Magnus Simren; Jessica Sjolund; Navkiran Tornkvist; Uday C. Ghoshal; Olga Kolokolnikova; Antonio Colecchia; Jordi Serra; Giovanni Maconi; Roberto De Giorgio; Silvio Danese; Pietro Portincasa; Michele Di Stefano; Marcello Maggio; Elena Philippou; Yeong Yeh Lee; Alessandro Venturi; Claudio Borghi; Marco Zoli; Paolo Gionchetti; Pierluigi Viale; Vincenzo Stanghellini; Giovanni Barbara

doi:10.14309/ajg.0000000000001541

Prevalence of Gastrointestinal Symptoms in Severe Acute Respiratory Syndrome Coronavirus 2 Infection: Results of the Prospective Controlled Multinational GI-COVID-19 Study

Giovanni Marasco, Cesare Cremon, Maria Raffaella Barbaro, Daniele Salvi, Giulia Cacciari, Anna Kagramanova, Dmitry Bordin, Vasile Drug, Edgidia Miftode, Pietro Fusaroli, Salem Youssef Mohamed, Chiara Ricci, Massimo Bellini, M. Masudur Rahman, Luigi Melcarne, Javier Santos, Beatriz Lobo, Serhat Bor, Suna Yapali, Deniz AkyolFerdane Pirincci Sapmaz, Yonca Yilmaz Urun, Tugce Eskazan, Altay Celebi, Huseyin Kacmaz, Berat Ebik, Hatice Cilem Binicier, Mehmet Sait Bugdayci, Munkhtsetseg Banzragch Yaǧci, Husnu Pullukcu, Berrin Yalinbas Kaya, Ali Tureyen, Ibrahim Hatemi, Elif Sitre Koc, Goktug Sirin, Ali Riza Caliskan, Goksel Bengi, Esra Ergun Alis, Snezana Lukic, Meri Trajkovska, Keren Hod, Dan Dumitrascu, Antonello Pietrangelo, Elena Corradini, Magnus Simren, Jessica Sjolund, Navkiran Tornkvist, Uday C. Ghoshal, Olga Kolokolnikova, Antonio Colecchia, Jordi Serra, Giovanni Maconi, Roberto De Giorgio, Silvio Danese, Pietro Portincasa, Michele Di Stefano, Marcello Maggio, Elena Philippou, Yeong Yeh Lee, Alessandro Venturi, Claudio Borghi, Marco Zoli, Paolo Gionchetti, Pierluigi Viale, Vincenzo Stanghellini, Giovanni Barbara

Research output: Contribution to journal › Article › peer-review

Abstract

INTRODUCTION: Gastrointestinal (GI) symptoms in coronavirus-19 disease (COVID-19) have been reported with great variability and without standardization. In hospitalized patients, we aimed to evaluate the prevalence of GI symptoms, factors associated with their occurrence, and variation at 1 month. METHODS: TheGI-COVID-19 is a prospective,multicenter, controlled study. Patientswith and without COVID-19 diagnosis were recruited at hospital admission and asked for GI symptoms at admission and after 1 month, using the validated Gastrointestinal Symptom Rating Scale questionnaire. RESULTS: The study included 2036 hospitalized patients. A total of 871 patients (575 COVID1and 296 COVID2) were included for the primary analysis. GI symptoms occurred more frequently in patients with COVID-19 (59.7%; 343/575 patients) than in the control group (43.2%; 128/296 patients) (P < 0.001). Patients with COVID-19 complained of higher presence or intensity of nausea, diarrhea, loose stools, and urgency as compared with controls. At a 1-month follow-up, a reduction in the presence or intensity of GI symptoms was found in COVID-19 patients with GI symptoms at hospital admission. Nausea remained increased over controls. Factors significantly associated with nausea persistence in COVID-19 were female sex, high body mass index, the presence of dyspnea, and increased C-reactive protein levels. DISCUSSION: The prevalence of GI symptoms in hospitalized patients with COVID-19 is higher than previously reported. Systemic and respiratory symptoms are often associated with GI complaints. Nausea may persist after the resolution of COVID-19 infection.

Original language	English
Pages (from-to)	147-157
Number of pages	11
Journal	American Journal of Gastroenterology
Volume	117
Issue number	1
DOIs	https://doi.org/10.14309/ajg.0000000000001541
Publication status	Published - 1 Jan 2022

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.14309/ajg.0000000000001541

Cite this

Marasco, G., Cremon, C., Barbaro, M. R., Salvi, D., Cacciari, G., Kagramanova, A., Bordin, D., Drug, V., Miftode, E., Fusaroli, P., Mohamed, S. Y., Ricci, C., Bellini, M., Rahman, M. M., Melcarne, L., Santos, J., Lobo, B., Bor, S., Yapali, S., ... Barbara, G. (2022). Prevalence of Gastrointestinal Symptoms in Severe Acute Respiratory Syndrome Coronavirus 2 Infection: Results of the Prospective Controlled Multinational GI-COVID-19 Study. American Journal of Gastroenterology, 117(1), 147-157. https://doi.org/10.14309/ajg.0000000000001541

@article{bfb0d078b619429fb7a4e2aa7713096a,

title = "Prevalence of Gastrointestinal Symptoms in Severe Acute Respiratory Syndrome Coronavirus 2 Infection: Results of the Prospective Controlled Multinational GI-COVID-19 Study",

abstract = "INTRODUCTION: Gastrointestinal (GI) symptoms in coronavirus-19 disease (COVID-19) have been reported with great variability and without standardization. In hospitalized patients, we aimed to evaluate the prevalence of GI symptoms, factors associated with their occurrence, and variation at 1 month. METHODS: TheGI-COVID-19 is a prospective,multicenter, controlled study. Patientswith and without COVID-19 diagnosis were recruited at hospital admission and asked for GI symptoms at admission and after 1 month, using the validated Gastrointestinal Symptom Rating Scale questionnaire. RESULTS: The study included 2036 hospitalized patients. A total of 871 patients (575 COVID1and 296 COVID2) were included for the primary analysis. GI symptoms occurred more frequently in patients with COVID-19 (59.7%; 343/575 patients) than in the control group (43.2%; 128/296 patients) (P < 0.001). Patients with COVID-19 complained of higher presence or intensity of nausea, diarrhea, loose stools, and urgency as compared with controls. At a 1-month follow-up, a reduction in the presence or intensity of GI symptoms was found in COVID-19 patients with GI symptoms at hospital admission. Nausea remained increased over controls. Factors significantly associated with nausea persistence in COVID-19 were female sex, high body mass index, the presence of dyspnea, and increased C-reactive protein levels. DISCUSSION: The prevalence of GI symptoms in hospitalized patients with COVID-19 is higher than previously reported. Systemic and respiratory symptoms are often associated with GI complaints. Nausea may persist after the resolution of COVID-19 infection. ",

author = "Giovanni Marasco and Cesare Cremon and Barbaro, {Maria Raffaella} and Daniele Salvi and Giulia Cacciari and Anna Kagramanova and Dmitry Bordin and Vasile Drug and Edgidia Miftode and Pietro Fusaroli and Mohamed, {Salem Youssef} and Chiara Ricci and Massimo Bellini and Rahman, {M. Masudur} and Luigi Melcarne and Javier Santos and Beatriz Lobo and Serhat Bor and Suna Yapali and Deniz Akyol and Sapmaz, {Ferdane Pirincci} and Urun, {Yonca Yilmaz} and Tugce Eskazan and Altay Celebi and Huseyin Kacmaz and Berat Ebik and Binicier, {Hatice Cilem} and Bugdayci, {Mehmet Sait} and Yaǧci, {Munkhtsetseg Banzragch} and Husnu Pullukcu and Kaya, {Berrin Yalinbas} and Ali Tureyen and Ibrahim Hatemi and Koc, {Elif Sitre} and Goktug Sirin and Caliskan, {Ali Riza} and Goksel Bengi and Alis, {Esra Ergun} and Snezana Lukic and Meri Trajkovska and Keren Hod and Dan Dumitrascu and Antonello Pietrangelo and Elena Corradini and Magnus Simren and Jessica Sjolund and Navkiran Tornkvist and Ghoshal, {Uday C.} and Olga Kolokolnikova and Antonio Colecchia and Jordi Serra and Giovanni Maconi and {De Giorgio}, Roberto and Silvio Danese and Pietro Portincasa and {Di Stefano}, Michele and Marcello Maggio and Elena Philippou and Lee, {Yeong Yeh} and Alessandro Venturi and Claudio Borghi and Marco Zoli and Paolo Gionchetti and Pierluigi Viale and Vincenzo Stanghellini and Giovanni Barbara",

note = "Funding Information: Financial support : G.B. contribution to this research was permitted in part by funding from Fondazione Cassa di Risparmio in Bologna; the Italian Ministry of Education, University and Research; and Fondazione del Monte di Bologna e Ravenna and European Grant H2020, DISCOvERIE, SC1-BHC-01-2019. M.R.B. is a recipient of a grant from the Italian Ministry of Health (Ricerca Finalizzata GR-2018-12367062). None of the funding organizations have had any role in the design and conduct of the study; in the collection, management, and analysis of the data; or in the preparation, review, and approval of the article. Publisher Copyright: {\textcopyright} 2021 by The American College of Gastroenterology.",

year = "2022",

month = jan,

day = "1",

doi = "10.14309/ajg.0000000000001541",

language = "English",

volume = "117",

pages = "147--157",

journal = "American Journal of Gastroenterology",

issn = "0002-9270",

publisher = "Wolters Kluwer Health",

number = "1",

}

Marasco, G, Cremon, C, Barbaro, MR, Salvi, D, Cacciari, G, Kagramanova, A, Bordin, D, Drug, V, Miftode, E, Fusaroli, P, Mohamed, SY, Ricci, C, Bellini, M, Rahman, MM, Melcarne, L, Santos, J, Lobo, B, Bor, S, Yapali, S, Akyol, D, Sapmaz, FP, Urun, YY, Eskazan, T, Celebi, A, Kacmaz, H, Ebik, B, Binicier, HC, Bugdayci, MS, Yaǧci, MB, Pullukcu, H, Kaya, BY, Tureyen, A, Hatemi, I, Koc, ES, Sirin, G, Caliskan, AR, Bengi, G, Alis, EE, Lukic, S, Trajkovska, M, Hod, K, Dumitrascu, D, Pietrangelo, A, Corradini, E, Simren, M, Sjolund, J, Tornkvist, N, Ghoshal, UC, Kolokolnikova, O, Colecchia, A, Serra, J, Maconi, G, De Giorgio, R, Danese, S, Portincasa, P, Di Stefano, M, Maggio, M, Philippou, E, Lee, YY, Venturi, A, Borghi, C, Zoli, M, Gionchetti, P, Viale, P, Stanghellini, V & Barbara, G 2022, 'Prevalence of Gastrointestinal Symptoms in Severe Acute Respiratory Syndrome Coronavirus 2 Infection: Results of the Prospective Controlled Multinational GI-COVID-19 Study', American Journal of Gastroenterology, vol. 117, no. 1, pp. 147-157. https://doi.org/10.14309/ajg.0000000000001541

Prevalence of Gastrointestinal Symptoms in Severe Acute Respiratory Syndrome Coronavirus 2 Infection: Results of the Prospective Controlled Multinational GI-COVID-19 Study. / Marasco, Giovanni; Cremon, Cesare; Barbaro, Maria Raffaella et al.
In: American Journal of Gastroenterology, Vol. 117, No. 1, 01.01.2022, p. 147-157.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Prevalence of Gastrointestinal Symptoms in Severe Acute Respiratory Syndrome Coronavirus 2 Infection

T2 - Results of the Prospective Controlled Multinational GI-COVID-19 Study

AU - Marasco, Giovanni

AU - Cremon, Cesare

AU - Barbaro, Maria Raffaella

AU - Salvi, Daniele

AU - Cacciari, Giulia

AU - Kagramanova, Anna

AU - Bordin, Dmitry

AU - Drug, Vasile

AU - Miftode, Edgidia

AU - Fusaroli, Pietro

AU - Mohamed, Salem Youssef

AU - Ricci, Chiara

AU - Bellini, Massimo

AU - Rahman, M. Masudur

AU - Melcarne, Luigi

AU - Santos, Javier

AU - Lobo, Beatriz

AU - Bor, Serhat

AU - Yapali, Suna

AU - Akyol, Deniz

AU - Sapmaz, Ferdane Pirincci

AU - Urun, Yonca Yilmaz

AU - Eskazan, Tugce

AU - Celebi, Altay

AU - Kacmaz, Huseyin

AU - Ebik, Berat

AU - Binicier, Hatice Cilem

AU - Bugdayci, Mehmet Sait

AU - Yaǧci, Munkhtsetseg Banzragch

AU - Pullukcu, Husnu

AU - Kaya, Berrin Yalinbas

AU - Tureyen, Ali

AU - Hatemi, Ibrahim

AU - Koc, Elif Sitre

AU - Sirin, Goktug

AU - Caliskan, Ali Riza

AU - Bengi, Goksel

AU - Alis, Esra Ergun

AU - Lukic, Snezana

AU - Trajkovska, Meri

AU - Hod, Keren

AU - Dumitrascu, Dan

AU - Pietrangelo, Antonello

AU - Corradini, Elena

AU - Simren, Magnus

AU - Sjolund, Jessica

AU - Tornkvist, Navkiran

AU - Ghoshal, Uday C.

AU - Kolokolnikova, Olga

AU - Colecchia, Antonio

AU - Serra, Jordi

AU - Maconi, Giovanni

AU - De Giorgio, Roberto

AU - Danese, Silvio

AU - Portincasa, Pietro

AU - Di Stefano, Michele

AU - Maggio, Marcello

AU - Philippou, Elena

AU - Lee, Yeong Yeh

AU - Venturi, Alessandro

AU - Borghi, Claudio

AU - Zoli, Marco

AU - Gionchetti, Paolo

AU - Viale, Pierluigi

AU - Stanghellini, Vincenzo

AU - Barbara, Giovanni

N1 - Funding Information: Financial support : G.B. contribution to this research was permitted in part by funding from Fondazione Cassa di Risparmio in Bologna; the Italian Ministry of Education, University and Research; and Fondazione del Monte di Bologna e Ravenna and European Grant H2020, DISCOvERIE, SC1-BHC-01-2019. M.R.B. is a recipient of a grant from the Italian Ministry of Health (Ricerca Finalizzata GR-2018-12367062). None of the funding organizations have had any role in the design and conduct of the study; in the collection, management, and analysis of the data; or in the preparation, review, and approval of the article. Publisher Copyright: © 2021 by The American College of Gastroenterology.

PY - 2022/1/1

Y1 - 2022/1/1

N2 - INTRODUCTION: Gastrointestinal (GI) symptoms in coronavirus-19 disease (COVID-19) have been reported with great variability and without standardization. In hospitalized patients, we aimed to evaluate the prevalence of GI symptoms, factors associated with their occurrence, and variation at 1 month. METHODS: TheGI-COVID-19 is a prospective,multicenter, controlled study. Patientswith and without COVID-19 diagnosis were recruited at hospital admission and asked for GI symptoms at admission and after 1 month, using the validated Gastrointestinal Symptom Rating Scale questionnaire. RESULTS: The study included 2036 hospitalized patients. A total of 871 patients (575 COVID1and 296 COVID2) were included for the primary analysis. GI symptoms occurred more frequently in patients with COVID-19 (59.7%; 343/575 patients) than in the control group (43.2%; 128/296 patients) (P < 0.001). Patients with COVID-19 complained of higher presence or intensity of nausea, diarrhea, loose stools, and urgency as compared with controls. At a 1-month follow-up, a reduction in the presence or intensity of GI symptoms was found in COVID-19 patients with GI symptoms at hospital admission. Nausea remained increased over controls. Factors significantly associated with nausea persistence in COVID-19 were female sex, high body mass index, the presence of dyspnea, and increased C-reactive protein levels. DISCUSSION: The prevalence of GI symptoms in hospitalized patients with COVID-19 is higher than previously reported. Systemic and respiratory symptoms are often associated with GI complaints. Nausea may persist after the resolution of COVID-19 infection.

AB - INTRODUCTION: Gastrointestinal (GI) symptoms in coronavirus-19 disease (COVID-19) have been reported with great variability and without standardization. In hospitalized patients, we aimed to evaluate the prevalence of GI symptoms, factors associated with their occurrence, and variation at 1 month. METHODS: TheGI-COVID-19 is a prospective,multicenter, controlled study. Patientswith and without COVID-19 diagnosis were recruited at hospital admission and asked for GI symptoms at admission and after 1 month, using the validated Gastrointestinal Symptom Rating Scale questionnaire. RESULTS: The study included 2036 hospitalized patients. A total of 871 patients (575 COVID1and 296 COVID2) were included for the primary analysis. GI symptoms occurred more frequently in patients with COVID-19 (59.7%; 343/575 patients) than in the control group (43.2%; 128/296 patients) (P < 0.001). Patients with COVID-19 complained of higher presence or intensity of nausea, diarrhea, loose stools, and urgency as compared with controls. At a 1-month follow-up, a reduction in the presence or intensity of GI symptoms was found in COVID-19 patients with GI symptoms at hospital admission. Nausea remained increased over controls. Factors significantly associated with nausea persistence in COVID-19 were female sex, high body mass index, the presence of dyspnea, and increased C-reactive protein levels. DISCUSSION: The prevalence of GI symptoms in hospitalized patients with COVID-19 is higher than previously reported. Systemic and respiratory symptoms are often associated with GI complaints. Nausea may persist after the resolution of COVID-19 infection.

UR - http://www.scopus.com/inward/record.url?scp=85121709570&partnerID=8YFLogxK

U2 - 10.14309/ajg.0000000000001541

DO - 10.14309/ajg.0000000000001541

M3 - Article

C2 - 34751672

AN - SCOPUS:85121709570

SN - 0002-9270

VL - 117

SP - 147

EP - 157

JO - American Journal of Gastroenterology

JF - American Journal of Gastroenterology

IS - 1

ER -

Prevalence of Gastrointestinal Symptoms in Severe Acute Respiratory Syndrome Coronavirus 2 Infection: Results of the Prospective Controlled Multinational GI-COVID-19 Study

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this